BRPI1013933A2 - 3-azabiciclo [4.1.0] heptanos usados como antagonistas de orexina - Google Patents

3-azabiciclo [4.1.0] heptanos usados como antagonistas de orexina

Info

Publication number
BRPI1013933A2
BRPI1013933A2 BRPI1013933A BRPI1013933A BRPI1013933A2 BR PI1013933 A2 BRPI1013933 A2 BR PI1013933A2 BR PI1013933 A BRPI1013933 A BR PI1013933A BR PI1013933 A BRPI1013933 A BR PI1013933A BR PI1013933 A2 BRPI1013933 A2 BR PI1013933A2
Authority
BR
Brazil
Prior art keywords
heptanes
azabicyclo
orexin antagonists
orexin
antagonists
Prior art date
Application number
BRPI1013933A
Other languages
English (en)
Inventor
Amantini David
Pavone Francesca
Ferroni Francesco
Gianotti Massimo
Di Fabio Romano
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0907112A external-priority patent/GB0907112D0/en
Priority claimed from GB0910483A external-priority patent/GB0910483D0/en
Priority claimed from GB0922472A external-priority patent/GB0922472D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI1013933A2 publication Critical patent/BRPI1013933A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI1013933A 2009-04-24 2010-04-23 3-azabiciclo [4.1.0] heptanos usados como antagonistas de orexina BRPI1013933A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0907112A GB0907112D0 (en) 2009-04-24 2009-04-24 Novel compounds
GB0910483A GB0910483D0 (en) 2009-06-17 2009-06-17 Novel compounds
GB0922472A GB0922472D0 (en) 2009-12-22 2009-12-22 Novel compounds
PCT/EP2010/055449 WO2010122151A1 (en) 2009-04-24 2010-04-23 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists

Publications (1)

Publication Number Publication Date
BRPI1013933A2 true BRPI1013933A2 (pt) 2017-06-13

Family

ID=42212163

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013933A BRPI1013933A2 (pt) 2009-04-24 2010-04-23 3-azabiciclo [4.1.0] heptanos usados como antagonistas de orexina

Country Status (14)

Country Link
US (1) US20120040991A1 (pt)
EP (1) EP2421850A1 (pt)
JP (1) JP2012524760A (pt)
KR (1) KR20120007061A (pt)
CN (1) CN102459229A (pt)
AU (1) AU2010240871A1 (pt)
BR (1) BRPI1013933A2 (pt)
CA (1) CA2759160A1 (pt)
EA (1) EA201171293A1 (pt)
IL (1) IL215616A0 (pt)
MX (1) MX2011011127A (pt)
SG (1) SG175026A1 (pt)
WO (1) WO2010122151A1 (pt)
ZA (1) ZA201107205B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02437B (me) 2009-10-23 2016-09-20 Janssen Pharmaceutica Nv Disupstituirani oktahidropirolo[3,4-c]piroli kao modulatori oreksin receptora
US9012636B2 (en) * 2010-10-29 2015-04-21 Merck Sharp & Dohme Corp. Process for the preparation of an orexin receptor antagonist
WO2012089606A1 (en) * 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
WO2012089607A1 (en) * 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
ITMI20112329A1 (it) * 2011-12-21 2013-06-22 Rottapharm Spa Nuovi derivati spiro amminici
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
KR20140124398A (ko) 2012-02-07 2014-10-24 이올라스 테라퓨틱스, 인코포레이티드 오렉신 수용체 길항제로서 치환된 프롤린 / 피페리딘
ITMI20120424A1 (it) 2012-03-19 2013-09-20 Rottapharm Spa Composti chimici
SI2855453T1 (sl) 2012-06-04 2017-05-31 Actelion Pharmaceuticals Ltd. Benzimidazol-prolinski derivati
EA201500399A1 (ru) 2012-10-10 2015-09-30 Актелион Фармасьютиклз Лтд. Антагонисты рецептора орексина, которые представляют собой производные [орто-би-(гетеро)арил]-[2-(мета-би-(гетеро)арил)пирролидин-1-ил]метанона
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
UA119549C2 (uk) 2013-12-03 2019-07-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ТА ЇЇ ЗАСТОСУВАННЯ ЯК АНТАГОНІСТА ОРЕКСИНОВОГО РЕЦЕПТОРА
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
PT3077391T (pt) 2013-12-04 2018-11-26 Idorsia Pharmaceuticals Ltd Utilização de derivados de benzimidazol-prolina
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
UY36272A (es) 2014-08-13 2016-02-29 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores de los receptores de orexinas
CA2960791C (en) 2014-09-11 2023-03-14 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
CN106146585B (zh) * 2015-04-10 2019-05-28 正大天晴药业集团股份有限公司 氘修饰的脲苷衍生物
CA3013927C (en) 2016-02-12 2024-02-13 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
EA201891930A1 (ru) 2016-03-10 2019-02-28 Янссен Фармацевтика Нв Способы лечения депрессии с использованием антагонистов орексиновых рецепторов-2
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
GB2558975B (en) * 2017-09-01 2019-01-23 Chronos Therapeutics Ltd Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
AU2018326734B2 (en) 2017-09-01 2023-08-17 Chronos Therapeutics Limited Substituted 2-azabicyclo(3.1.1)heptane and 2-azabicyclo(3.2.1)octane derivatives as orexin receptor antagonists
WO2019081939A1 (en) * 2017-10-25 2019-05-02 Chronos Therapeutics Limited 2-AZABICYCLO [3.1.1] DERIVATIVES AS ANTAGONISTS OF OREXIN-1 AND OREXIN-2 RECEPTORS
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
CA3149096A1 (en) 2019-07-30 2021-02-04 Eikonizo Therapapeutics, Inc. Hdac6 inhibitors and uses thereof
PH12022551475A1 (en) 2019-12-20 2023-11-29 Tenaya Therapeutics Inc Fluoroalkyl-oxadiazoles and uses thereof
CA3216768A1 (en) 2021-05-04 2022-11-10 Jin Yang 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
AR129309A1 (es) 2022-05-13 2024-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidrazina-n-carboxamida cíclica sustituida con tiazoloaril-metilo
WO2026019302A1 (ko) * 2024-07-18 2026-01-22 (주)셀트리온 신규한 오렉신 2 수용체 작용제 및 이의 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462856A (en) 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc HUMAN NEUROPEPTIDE RECEPTOR
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
AR016817A1 (es) 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
EP1075478B1 (en) 1998-05-08 2003-04-16 SmithKline Beecham plc Phenylurea and phenylthio urea derivatives
WO2000047580A2 (en) 1999-02-12 2000-08-17 Smithkline Beecham Plc Phenyl urea and phenyl thiourea derivatives
WO2000047576A1 (en) 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
US6699879B1 (en) 1999-02-12 2004-03-02 Smithkline Beecham P.L.C. Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
ATE293101T1 (de) 2000-06-16 2005-04-15 Smithkline Beecham Plc Piperidine zur verwendung als orexin rezeptor antagonisten
JP4246490B2 (ja) 2000-11-28 2009-04-02 スミスクライン ビーチャム ピー エル シー オレキシン受容体のアンタゴニストとしてのモルホリン誘導体
JP2004534026A (ja) * 2001-05-05 2004-11-11 スミスクライン ビーチャム パブリック リミテッド カンパニー オレキシン受容体アンタゴニストとしてのn−アロイルサイクリックアミン誘導体
CN1549816A (zh) 2001-06-28 2004-11-24 ʷ 作为阿立新受体拮抗药的n-芳酰基环胺衍生物
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130335D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
DK1751111T3 (en) 2004-03-01 2015-02-09 Actelion Pharmaceuticals Ltd SUBSTITUTED 1,2,3,4-tetrahydroisoquinoline derivatives
KR20090077051A (ko) * 2006-09-29 2009-07-14 액테리온 파마슈티칼 리미티드 3-아자-비시클로[3.1.0]헥산 유도체
JP2010528007A (ja) * 2007-05-23 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション シクロプロピルピロリジンオレキシン受容体アンタゴニスト
AR067396A1 (es) 2007-07-03 2009-10-07 Glaxo Group Ltd Compuesto derivado de imidazo(1,2-a)piridin-2-ilmetil piperidina sustituida sal hidrocloruro del mismo uso del compuesto o de la sal hidrocloruro para la preparacion de un medicamento y composiciones farmaceuticas que los comprende
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
KR20120007061A (ko) 2012-01-19
AU2010240871A1 (en) 2011-10-27
CN102459229A (zh) 2012-05-16
CA2759160A1 (en) 2010-10-28
SG175026A1 (en) 2011-11-28
IL215616A0 (en) 2011-12-29
WO2010122151A1 (en) 2010-10-28
ZA201107205B (en) 2012-05-30
EP2421850A1 (en) 2012-02-29
EA201171293A1 (ru) 2012-05-30
MX2011011127A (es) 2011-11-18
JP2012524760A (ja) 2012-10-18
US20120040991A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
BRPI1013933A2 (pt) 3-azabiciclo [4.1.0] heptanos usados como antagonistas de orexina
FR22C1020I2 (fr) Antagonistes de c5ar
BRPI1008939A2 (pt) 2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.
BRPI1009415A2 (pt) escova de dentes.
BRPI1013821A2 (pt) piridinas substituídas como antagonistas de ccr3.
ECSP12012034A (es) Antagonistas de pcsk9
CU24152B1 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
BRPI1011694A2 (pt) similadores de categoria
DK2494147T3 (da) Scanningsværktøj
LT3093291T (lt) Dipakeistieji oktahidropirolo [3,4-c]pirolai, kaip oreksino receptoriaus moduliatoriai
BR112012028519A2 (pt) compostos de 2,5,6,7-tetrahidro-[1,4]oxazepin-3-ilamina ou 2,3,6,7-tetrahidro-[1,4]oxazepin-5-ilamina
BRPI1008899A2 (pt) derivados 3,3´-espiroindolinona como agentes anticâncer
BRPI0813768A2 (pt) Derivados de benzazepina úteis como antagonistas de vasopressina
BR112012003701A2 (pt) "novos antagonistas de quinolina-hepcidina"
BRPI0814806A2 (pt) Pirazinas substituídas como antagonistas de cb1
BR112013007850A2 (pt) 1,2-diidro-4-hidróxi-2-oxo-quinolina-3-carboxanilidas como ativadores de ahr
BRPI1011460A2 (pt) Composição desinfetante.
BRPI0814767A2 (pt) Derivados de monoamida como antagonistas do receptor de orexina
BRPI1009428A2 (pt) 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3
BRPI0914596A2 (pt) combinação de guindaste
IL212571A0 (en) Aryl piperazine and their use as alpha2c antagonists
BR212012009026U2 (pt) escova de dentes
BR112012003591A2 (pt) conjunto de recipientes
BRPI1016207A2 (pt) compostos de 4-azetidinil-1-heteroaril-ciclohexano antagonistas de ccr2
ES1070267Y (es) Deposito de heces equino

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]